Mohammad Alyamani

Dr. Mohammad Alyamani

Cleveland Clinic Foundation, Cleveland, OH, USA
orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2015 in Nature
Verified
Journal Article
Closed access
PDF file
ZLZhenfei Li
Zhenfei Li
ABAndrew C. Bishop
Andrew C. Bishop
Mohammad AlyamaniMohammad Alyamani
Mohammad Alyamani
JGJorge A. Garcia
Jorge A. Garcia
RDRobert Dreicer
Robert Dreicer
NSNima Sharifi
Nima Sharifi

25 May 2016 in Nature
Verified
Journal Article
Open access
PDF file
ZLZhenfei Li
Zhenfei Li
Mohammad AlyamaniMohammad Alyamani
Mohammad Alyamani
JLJianneng Li
Jianneng Li
KRKevin Rogacki
Kevin Rogacki
MAMohamed Abazeed
Mohamed Abazeed
NSNima Sharifi
Nima Sharifi
The prostate cancer drug abiraterone can be metabolized into several substances with different effects, and optimization of this process could be helpful for fine-tuning the treatment of prostate cancer. The anti-androgen prostate cancer drug abiraterone is metabolized in the body to Δ4-abiraterone (D4A), a more potent steroid than abiraterone with structural similarities to endogenous steroidal 5α-reductase substrates, such as testosterone. These authors show that D4A is converted in the body to at least six previously unrecognized metabolites with a range of different metabolic effects. In a clinical trial of abiraterone alone, followed by abiraterone plus the 5α-reductase inhibitor dutasteride, production of a downstream tumour-promoting metabolite was blocked and D4A concentrations rose. These findings suggest a previously unappreciated method of clinically fine-tuning abiraterone metabolism to optimize cancer therapy. Abiraterone blocks androgen synthesis and prolongs survival in patients with castration-resistant prostate cancer, which is otherwise driven by intratumoral androgen synthesis1,2. Abiraterone is metabolized in patients to Δ4-abiraterone (D4A), which has even greater anti-tumour activity and is structurally similar to endogenous steroidal 5α-reductase substrates, such as testosterone3. Here, we show that D4A is converted to at least three 5α-reduced and three 5β-reduced metabolites in human serum. The initial 5α-reduced metabolite, 3-keto-5α-abiraterone, is present at higher concentrations than D4A in patients with prostate cancer taking abiraterone, and is an androgen receptor agonist, which promotes prostate cancer progression. In a clinical trial of abiraterone alone, followed by abiraterone plus dutasteride (a 5α-reductase inhibitor), 3-keto-5α-abiraterone and downstream metabolites were depleted by the addition of dutasteride, while D4A concentrations rose, showing that dutasteride effectively blocks production of a tumour-promoting metabolite and permits D4A accumulation. Furthermore, dutasteride did not deplete the three 5β-reduced metabolites, which were also clinically detectable, demonstrating the specific biochemical effects of pharmacological 5α-reductase inhibition on abiraterone metabolism. Our findings suggest a previously unappreciated and biochemically specific method of clinically fine-tuning abiraterone metabolism to optimize therapy.

13 February 2017 in eLife
Verified
Journal Article
Open access
JLJianneng Li
Jianneng Li
Mohammad AlyamaniMohammad Alyamani
Mohammad Alyamani
AZAo Zhang
Ao Zhang
KCKai-Hsiung Chang
Kai-Hsiung Chang
MBMichael Berk
Michael Berk
NSNima Sharifi
Nima Sharifi
Prostate cancer is driven by androgen stimulation of the androgen receptor (AR). The next-generation AR antagonist, enzalutamide, prolongs survival, but resistance and lethal disease eventually prevail. Emerging data suggest that the glucocorticoid receptor (GR) is upregulated in this context, stimulating expression of AR-target genes that permit continued growth despite AR blockade. However, countering this mechanism by administration of GR antagonists is problematic because GR is essential for life. We show that enzalutamide treatment in human models of prostate cancer and patient tissues is accompanied by a ubiquitin E3-ligase, AMFR, mediating loss of 11β-hydroxysteroid dehydrogenase-2 (11β-HSD2), which otherwise inactivates cortisol, sustaining tumor cortisol concentrations to stimulate GR and enzalutamide resistance. Remarkably, reinstatement of 11β-HSD2 expression, or AMFR loss, reverses enzalutamide resistance in mouse xenograft tumors. Together, these findings reveal a surprising metabolic mechanism of enzalutamide resistance that may be targeted with a strategy that circumvents a requirement for systemic GR ablation.

25 June 2018 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
Mohammad AlyamaniMohammad Alyamani
Mohammad Alyamani
HEHamid Emamekhoo
Hamid Emamekhoo
SPSunho Park
Sunho Park
JTJennifer Taylor
Jennifer Taylor
NANima Almassi
Nima Almassi
NSNima Sharifi
Nima Sharifi
BACKGROUND. A common germline variant in HSD3B1(1245A>C) encodes for a hyperactive 3β-hydroxysteroid dehydrogenase 1 (3βHSD1) missense that increases metabolic flux from extragonadal precursor steroids to DHT synthesis in prostate cancer. Enabling of extragonadal DHT synthesis by HSD3B1(1245C) predicts for more rapid clinical resistance to castration and sensitivity to extragonadal androgen synthesis inhibition. HSD3B1(1245C) thus appears to define a subgroup of patients who benefit from blocking extragonadal androgens. However, abiraterone, which is administered to block extragonadal androgens, is a steroidal drug that is metabolized by 3βHSD1 to multiple steroidal metabolites, including 3-keto-5α-abiraterone, which stimulates the androgen receptor. Our objective was to determine if HSD3B1(1245C) inheritance is associated with increased 3-keto-5α-abiraterone synthesis in patients. METHODS. First, we characterized the pharmacokinetics of 7 steroidal abiraterone metabolites in 15 healthy volunteers. Second, we determined the association between serum 3-keto-5α-abiraterone levels and HSD3B1 genotype in 30 patients treated with abiraterone acetate (AA) after correcting for the determined pharmacokinetics. RESULTS. Patients who inherit 0, 1, and 2 copies of HSD3B1(1245C) have a stepwise increase in normalized 3-keto-5α-abiraterone (0.04 ng/ml, 2.60 ng/ml, and 2.70 ng/ml, respectively; P = 0.002). CONCLUSION. Increased generation of 3-keto-5α-abiraterone in patients with HSD3B1(1245C) might partially negate abiraterone benefits in these patients who are otherwise more likely to benefit from CYP17A1 inhibition. FUNDING. Prostate Cancer Foundation Challenge Award, National Cancer Institute.

1 July 2017 in Cell Chemical Biology
Verified
Journal Article
Closed access
Mohammad AlyamaniMohammad Alyamani
Mohammad Alyamani
ZLZhenfei Li
Zhenfei Li
MBMichael Berk
Michael Berk
JLJianneng Li
Jianneng Li
JTJingjie Tang
Jingjie Tang
NSNima Sharifi
Nima Sharifi

3 April 2023 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
DCDi Cui
Di Cui
JLJianneng Li
Jianneng Li
ZZZiqi Zhu
Ziqi Zhu
MBMichael Berk
Michael Berk
AHAimalie Hardaway
Aimalie Hardaway
NSNima Sharifi
Nima Sharifi
After androgen deprivation, prostate cancer frequently becomes castration resistant (CRPC), with intratumoral androgen production from extragonadal precursors that activate the androgen receptor pathway. 3β-Hydroxysteroid dehydrogenase-1 (3βHSD1) is the rate-limiting enzyme for extragonadal androgen synthesis, which together lead to CRPC. Here, we show that cancer-associated fibroblasts (CAFs) increased epithelial 3βHSD1 expression, induced androgen synthesis, activated the androgen receptor, and induced CRPC. Unbiased metabolomics revealed that CAF-secreted glucosamine specifically induced 3βHSD1. CAFs induced higher GlcNAcylation in cancer cells and elevated expression of the transcription factor Elk1, which induced higher 3βHSD1 expression and activity. Elk1 genetic ablation in cancer epithelial cells suppressed CAF-induced androgen biosynthesis in vivo. In patient samples, multiplex fluorescent imaging showed that tumor cells expressed more 3βHSD1 and Elk1 in CAF-enriched areas compared with CAF-deficient areas. Our findings suggest that CAF-secreted glucosamine increases GlcNAcylation in prostate cancer cells, promoting Elk1-induced HSD3B1 transcription, which upregulates de novo intratumoral androgen synthesis to overcome castration.